Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

2009 ◽  
Vol 84 (5) ◽  
pp. 302-305 ◽  
Author(s):  
Yu-Yan Hwang ◽  
Eric Tse ◽  
Jason C.C. So ◽  
Thomas S.K. Wan ◽  
Yok-Lam Kwong
Keyword(s):  
Imatinib Mesylate ◽  
Chronic Myelogenous Leukemia ◽  
Chronic Phase ◽  
Myelogenous Leukemia

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome–positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

Blood ◽  
2003 ◽  
Vol 101 (1) ◽  
pp. 97-100 ◽  
Author(s):  
Hagop M. Kantarjian ◽  
Jorge E. Cortes ◽  
Susan O'Brien ◽  
Francis Giles ◽  
Guillermo Garcia-Manero ◽  
...  
Keyword(s):  
Imatinib Mesylate ◽  
Chronic Myelogenous Leukemia ◽  
Quantitative Polymerase Chain Reaction ◽  
Philadelphia Chromosome ◽  
Chronic Phase ◽  
Cytogenetic Response ◽  
Myelogenous Leukemia ◽  
Interferon Α ◽  
Combination Regimens ◽  
Philadelphia Chromosome Positive

Abstract Fifty patients with Philadelphia chromosome–positive (Ph+) chronic myelogenous leukemia (CML) in early chronic phase received imatinib mesylate, 400 mg orally daily. After a median follow-up of 9 months, 49 patients (98%) achieved a complete hematologic response and 45 patients (90%) achieved a major cytogenetic response, complete in 36 patients (72%). Compared with similar patients who received interferon-α with or without hydroxyurea or other interferon-α combination regimens, those receiving imatinib mesylate had higher incidences of complete and major (Ph < 35%) cytogenetic responses at 3 months (34% and 74% versus 1%-4% and 9%-24%, respectively), 6 months (52% and 80% versus 3%-7% and 11%-28%, respectively), and 9 months (60% and 77% versus 5%-11% and 14%-30%, respectively; P < .001). Competitive quantitative polymerase chain reaction (QPCR) studies at 9 months showed a median QPCR value (ratio of BCR-ABL/ABL transcripts × 100) of 0.59% overall and of 0.24% (range, 0.001%-29.5%) for complete cytogenetic response.

Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase

2006 ◽  
Vol 47 (7) ◽  
pp. 1427-1430 ◽  
Author(s):  
Rie Yamazaki ◽  
Shinichiro Okamoto ◽  
Chien-Kang Chen ◽  
Shinichiro Tada ◽  
Hidetane Saito ◽  
...  
Keyword(s):  
Liver Injury ◽  
Imatinib Mesylate ◽  
Chronic Myelogenous Leukemia ◽  
Chronic Phase ◽  
Myelogenous Leukemia ◽  
Successful Management

Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate

2005 ◽  
Vol 11 (9) ◽  
pp. 3425-3432 ◽  
Author(s):  
Jorge Cortes ◽  
Moshe Talpaz ◽  
Susan O'Brien ◽  
Dan Jones ◽  
Rajyalakshmi Luthra ◽  
...  
Keyword(s):  
Imatinib Mesylate ◽  
Chronic Myelogenous Leukemia ◽  
Chronic Phase ◽  
Myelogenous Leukemia ◽  
Molecular Responses

Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: Results of the AFR04 study

2012 ◽  
Vol 88 (1) ◽  
pp. 1-4 ◽  
Author(s):  
Philippe Rousselot ◽  
Pascale Cony-Makhoul ◽  
Franck Nicolini ◽  
François Xavier Mahon ◽  
Christian Berthou ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Imatinib Mesylate ◽  
Chronic Myelogenous Leukemia ◽  
Chronic Phase ◽  
Myelogenous Leukemia ◽  
Safety And Efficacy

scholarly journals Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience

2010 ◽  
Vol 67 (10) ◽  
pp. 802-806 ◽  
Author(s):  
Irena Cojbasic ◽  
Lana Macukanovic-Golubovic
Keyword(s):  
Tyrosine Kinase ◽  
Imatinib Mesylate ◽  
Median Time ◽  
Chronic Myelogenous Leukemia ◽  
Kinase Inhibitor ◽  
Specific Activity ◽  
Chronic Phase ◽  
Previous Treatment ◽  
Cytogenetic Response ◽  
Myelogenous Leukemia

Background/Aim. Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against the breakpoint cluster region - Abelson murine leukemia (BCR-ABL) tyrosine kinase has been developed for treatment of chronic myelogenous leukemia (CML). Its hematologic and cytogenetic effects have been evaluated in a series of clinical trials. The aim of this study was to report hematologic and cytogenetic response in CML patients during the treatment with imatinib mesylate. Methods. A total of 21 patients were treated and observed from July 2006 to December 2008. The median time from CML diagnosis was no more than 12 months, so all the patients received previous treatment with hydroxyurea for which the median time was 3 months. The patients received imatinib mesylate in an effective oral dose of 400 to 800 mg daily, which was followed with peripheral blood counts, bone marrow examination, and cytogenetic studies at 6, 12, 18 and 24 months. Results. Complete hematologic responses were reported for 19 (90.48%) of 21 patients studied. Among 19 patients who had a response, 16 (86%) did so within 3 months. The best cytogenetic response rate at any time during the study treatment with imatinib mesylate, among 14 patients in which cytogenetic response evaluated was: complete cytogenetic response in 7 (50%) patients, partial cytogenetic response in 6 (42.9%) patients and minor cytogenetic response in 1 (7.1%) patient. No patients had progressed to accelerated or blastic phase. The most frequent adverse effects that seemed to be related to treatment with imatinib mesylate were edema and musculosceletal pain; overall, most were mild. Only one patient discontinued treatment because of hematologic toxic effects. Conclusion. The results obtained in this study confirm that imatinib mesylate induces a complete hematological and cytogenetic response in a high percentage of patients with chronic-phase CML.

Sign in / Sign up

Export Citation Format

Share Document